| Literature DB >> 28399930 |
Anne M Selvaag1, Eva Kirkhus2,3, Lena Törnqvist2,4, Vibke Lilleby5, Hanne A Aulie5,6, Berit Flatø5,3.
Abstract
BACKGROUND: There are few studies on radiographic outcome after long-term disease duration in juvenile idiopathic arthritis (JIA). We wanted to evaluate 29-year radiographic outcome in hands/wrists and predictors of damage in patients with long-term active JIA.Entities:
Keywords: Disease progression; Follow-up studies; Juvenile idiopathic arthritis; Longitudinal studies; Prognosis; Radiography; Risk factors
Mesh:
Year: 2017 PMID: 28399930 PMCID: PMC5387251 DOI: 10.1186/s12969-017-0151-7
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Fig. 1Flow chart of how the 60 patients were selected from the original cohort of 260 patients
Demographic and clinical characteristics of 60 patients with JIA after 29 years of disease duration
| Characteristics | Value |
|---|---|
| Age, years | 38.2 (30–45) |
| Female | 42 (70) |
| Disease duration, years | 29.4 (26–38) |
| Number of swollen joints | 0 (0–12) |
| Number of tender joints | 1 (0–16) |
| Number of joints with LROM | 4 (0–56) |
| Number of active joints | 0 (0–13) |
| PGA, VAS cm | 1.5 (1–7.6) |
| Patient’s global well-being, VAS cm | 2.0 (1–5.9) |
| HAQ | 0.5 (0–1.6) |
| JADAS | 4.8 (0.2–27.1) |
| JADI total | 6 (0–73) |
| CRP, mg/l | 2.0 (0–38) |
| ESR, mm/h | 6.0 (2–60) |
| Vitamin A μmol/L | 1.6 (0.9–2.4) |
| Vitamin D nmol/L | 64 (26–100) |
| Patients in remission off medication | 12 (20) |
| Patients with inactive disease on medication | 8 (13) |
| Patients with persistently active disease | 40 (67) |
| Patients on sDMARDs | 19 (32) |
| Patients on biological immunosuppressants | 21 (35) |
| Patients on glucocorticosteroids | 6 (10) |
| Employeda | 46 (77) |
Numbers are median (range) or number (%). aEmployed is full or part time
LROM limited range of motion, PGA physician’s global assessment of disease activity, JADAS juvenile arthritis disease activity score, JADI juvenile arthritis damage index, sDMARDs synthetic disease-modifying anti-rheumatic drugs
The aSvdH score in hands and wrists of patients with JIA at 29-year follow-up
| JIA categories | No. of patients | No. of patients with a score > 0 | Total aSvdH score | Erosion score | JSN score | JADI | JADI | JADI |
|---|---|---|---|---|---|---|---|---|
| Total | 60 (100) | 33 (55) | 4 (0–313) | 1 (0–205) | 3 (0–110) | 5 (0–68) | 1 (0–7) | 6 (0–73) |
| Systemic arthritis | 3 (5) | 3 (100) | 45 (28–121) | 25 (10–75) | 20 (18–46) | 13 (8–24) | 1 (0–2) | 13 (9–26) |
| Polyarticular RF-negative | 11 (18) | 8 (61) | 22 (0–131) | 5 (0–76) | 8 (0–69) | 8 (0–36) | 1 (0–2) | 6 (0–38) |
| Polyarticular RF-positive | 5 (8) | 4 (80) | 222 (0–313)a | 127 (0–205)b | 95 (0–108)b | 30 (0–68) | 1 (0–5) | 31 (0–73) |
| Persistent oligoarticular | 5 (8) | 1 (20) | 0 (0–3) | 0 (0–1) | 0 (0–2) | 0 | 1 (0–3) | 1 (0–3) |
| Extended oligoarticular | 10 (17) | 5 (50) | 3 (0–95) | 0 (0–56) | 3 (0–39) | 7 (0–24) | 1 (0–3) | 8 (0–24) |
| Enthesitis related arthritis | 13 (22) | 5 (38) | 0 (0–117) | 0 (0–69) | 0 (0–48) | 3 (8–28) | 1 (0–3) | 5 (0–30) |
| Psoriatic arthritis | 10 (17) | 5 (50) | 1 (0–115) | 1 (0–68) | 0 (0–47) | 3 (0–42) | 0 (0–2) | 3 (0–42) |
| Undifferentiated arthritis | 3 (5) | 2 (67) | 31 (0–308) | 25 (0–128) | 6 (0–110) | 7 (2–43) | 4 (0–7) | 11 (2–50) |
Numbers are median (range) or number (%). aSignificantly different from scores in patients with polyarticular RF-negative JIA, extended oligoarticular JIA, enthesitis related arthritis and psoriatic arthritis (all p < 0.05). bSignificantly different from scores in patients with polyarticular RF-negative JIA, persistent oligoarticular JIA, extended oligoarticular JIA, enthesitis related arthritis and psoriatic arthritis (all p < 0.05). aSvdH adapted Sharp van der Heijde, JSN joint space narrowing, JADI juvenile arthritis damage index
Fig. 2The distribution of the aSvdH scores according to JIA category. aSvdH = adapted Sharp van der Heijde, RF = rheumatoid factor
The CHR of patients with JIA at 29-year follow-up
| JIA categories | No. of patients | CHR Right | CHR Left | Mean CHR |
|---|---|---|---|---|
| Total | 60 (100) | 0.52 (0.31–.64) | 0.52 (0.31–0.63) | 0.49 (0.08) |
| Systemic arthritis | 3 (5) | 0.32 (0.31–0.48) | 0.34 (0.31–0.48) | 0.37 (0.09)a |
| Polyarticular RF-negative | 11 (18) | 0.51 (0.43–0.57) | 0.51 (0.31–0.59) | 0.50 (0.05) |
| Polyarticular RF-positive | 5 (8) | 0.31 (0.31–0.53) | 0.31 (0.31–0.53) | 0.35 (0.10)b |
| Persistent oligoarticular | 5 (8) | 0.56 (0.52–0.58) | 0.56 (0.52–0.56) | 0.55 (0.02) |
| Extended oligoarticular | 10 (17) | 0.50 (0.31–0.55) | 0.51 (0.47–0.56) | 0.50 (0.04) |
| Enthesitis related arthritis | 13 (22) | 0.55 (0.42–0.64) | 0.54 (0.31–0.62) | 0.54 (0.06) |
| Psoriatic arthritis | 10 (17) | 0.52 (0.32–0.62) | 0.52 (0.45–0.63) | 0.52 (0.06) |
| Undifferentiated arthritis | 3 (5) | 0.40 (0.31–0.53) | 0.40 (0.31–0.58) | 0.42 (0.12) |
Numbers are median (range), number (%) or mean (SD). aSignificantly different from scores in patients with persistent oligoarticular arthritis, enthesitis related arthritis and psoriatic arthritis (p < 0.05). bSignificantly different from scores in patients with polyarticular RF-negative JIA, persistent oligoarticular JIA, extended oligoarticular JIA, enthesitis related arthritis and psoriatic arthritis (p ≤ 0.005). CHR carpal height ratio
Correlations between radiographic scores and measures of disease damage and disease activity at 29-year follow-up
| aSvdH scores | Erosion scores | JSN scores | Mean CHR | |
|---|---|---|---|---|
| Variables | 4.0 (0–313) | 1.0 (0–205) | 3.0 (0–110) | 0.52 (0.31–0.63) |
| JADI total | 0.706a | 0.721a | 0.714a | −0.660a |
| Joints with LROM | 0.669a | 0.659a | 0.665a | −0.645a |
| JADAS | 0.268b | 0.255b | 0.266b | NS |
| HAQ | NS | 0.278b | 0.259b | NS |
| CRP | 0.266b | NS | 0.273b | NS |
| Vitamin A | −0.272b | −0.275b | −0.299b | 0.430a |
Numbers are median scores (range) and Spearman’s correlation coefficients. The radiographic scores did not correlate with the number of swollen, tender and active joints, pain, well-being, ESR or vitamin D. a p ≤ 0.001, b p < 0.05. aSvdH adapted Sharp van der Heijde, JSN joint space narrowing, CHR carpal height ratio, JADI juvenile arthritis damage index, LROM limited range of motion, JADAS juvenile arthritis disease activity score, NS not significant
Predictors of the aSvdH score and mean CHR at 29-year follow-up
| aSvdH | Mean CHR | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analyses | Multivariate analyses | Univariate analyses | Multivariate analyses | |||||
| Variables assessed within 15 years: | B (95% CI) |
| B (95% CI) |
| B (95% CI) |
| B (95% CI) |
|
| Oligoarticular onseta | −48.1 (−85.3 to −10.9) | 0.012 | 0.047 (0.005 to 0.090) | 0.028 | ||||
| Polyarticular courseb | NA | NA | −0.060 (−0.120 to 0.000) | 0.048 | ||||
| HLA-DRB1*04 positive | 67.2 (28.8 to 105.5) | 0.001 | NA | NA | ||||
| HLA-B27 positive | NA | NA | 0.057 (0.011 to 0.102) | 0.016 | 0.047 (0.013 to 0.082) | 0.009 | ||
| No. joints with LROM at 15 yearsc | 5.9 (4.7 to 7.2) | <0.001 | 4.8 (3.4 to 6.3) | <0.001 | −0.005 (−0.007 to−0.004) | <0.001 | −0.004 (−0.006 to−0.002) | <0.001 |
| ESR at 15 years, mm/h | 2.6 (1.7 to 3.5) | <0.001 | 1.1 (0.3 to 1.9) | 0.010 | −0.002 (−0.003 to−0.001) | <0.001 | ||
| CRP at 15 years, mg/l | 2.3 (1.2 to 3.3) | <0.001 | NA | NA | ||||
| HAQ at 15 years | 53.5 (22.2 to 84.7) | 0.001 | −0.065 (−0.100 to −0.031) | <0.001 | −0.042 (−0.071 to −0.012) | 0.007 | ||
| Total time with active disease at 15-year follow-up, years | 5.1 (1.0 to 9.1) | 0.015 | −0.007 (−0.011 to −0.002) | 0.005 | ||||
aOligoarticular onset: ≤ 4 active joints first 6 months, from all JIA categories except polyarticular JIA. bPolyarticular course: having in total ≥ 5 active joints after 6 months of disease, from all JIA categories except persistent oligoarticular JIA. cNumber of joints with LROM at 15 years correlated highly (r >0.7) with physician’s global assessment and number of active joints at 15 years so only joints with LROM was chosen in the model. aSvdH adapted Sharp van der Heijde, CHR carpal height ratio, LROM limited range of motion, NA not applicable